Home > Insider Trading > Filing (0001410939-23-000027)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410939	Iveric Bio Inc.	ISEE	Pharmaceutical Preparations (2834)	208185347

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1696429	Keith Westby	C/O Iveric Bio, Inc. 8 Sylvan Way Parsippany NJ 07054	Svp, Chief Operating Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-02	13,298	$1.45	59,652	No	4	M	Direct
Common Stock	Disposition	2023-03-02	19,400	$23.91	40,252	No	4	S	Direct
Common Stock	Disposition	2023-03-02	600	$24.60	39,652	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2023-03-02	13,298	$1.45	13,298	$1.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,786		2028-12-11	No	4	M	Direct

Footnotes

The sale reported on this form was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 16, 2022.
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $23.51 to $24.49 per share on March 2, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $24.51 to $24.66 per share on March 2, 2023. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
This stock option award was granted on December 12, 2018 and vested with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.